Category Archives: Stem Cell Clinic

At NSUH, a cell of the century in the Don Monti unit – Innovate Long Island


That light at the end of the tunnel comes from the Northwell Health Cancer Institute, which provided hope and bona fide bone marrowy health improvements to a record number of patients last year.

As 2019 ticked down, staffers of the NHCIs Don Monti Adult Stem Cell Transplant Program gathered inside North Shore University Hospitalto recognize what Ruthee Lu-Bayer, chief of the Don Monti Bone Marrow Transplantation Unit, called a monumental milestone: the units 100th stem cell transplant of the year.

While any cancer clinic worth its salt is going to embrace hope, joy can be a rare commodity but the 100th stem cell transplant of 2019 triggered a full-on celebration at the Manhasset hospital, where stem cell transplants began in 1987 and are now performed in the 10-bed, inpatient Don Monti unit.

Complete with balloons, cake and a salute to No. 100 herself cancer-battling patient Teresa OHalloran the celebration assembled the units myriad doctors, nurses and other professionals, with Bayer applauding the combined efforts of every member of our staff who made this moment happen.

I always say that getting through their diagnosis is half the battle, the board-certified medical oncologist noted. When our patients arrive for transplant, I ask them to think of their transplant date as their second birthday, a time when they can begin to live their lives again.

Century mark: Don Monti Bone Marrow Transplantation Unit chief Ruthee Lu-Bayer and No. 100, Teresa OHalloran.

The gathering was also a celebration of the patients themselves, Bayer added, including OHalloran, whos fighting back against adult acute myeloid leukemia, a type of cancer in which the bone marrow produces abnormal white blood cells.

The 62-year-old East Islip resident, known affectionately as No. 100 around the unit, received the tough diagnosis last August and was admitted to NSUH in December for a bone marrow transplant. Following several days of preparatory chemotherapy, she received her infusion as the calendar flipped to 2020 and is now making an unusually rapid recovery, according to Northwell Health.

OHalloran, who joined the celebration from the safety of her isolated recovery room, credits her faith and positive outlook Ive always looked at the glass as half full, she noted and urged potential stem cell donors to check in with Be The Match, the national, nonprofit marrow-donor program.

I wish everyone could understand how important it is to be tested as a possible match, OHalloran added. Its a simple cheek swab and you could wind up saving someones life.

Visit link:
At NSUH, a cell of the century in the Don Monti unit - Innovate Long Island

Please Quit Telling Me It’s Not The Cancer –

A cancer survivor talks about the side effects of cancer and chemo few people truly understand.

She has myelodysplastic syndrome, which is rare, and would love to communicate with others who have MDS.

However, I monitor any additional medical problems that I did not have before my cancer diagnosis. If it pops up afterward, there may be a reason. It is time to get online and to talk to my doctor about whether it is related to my cancer or treatment.

Recently, a friend came to my book club bruised from a fall after two stem cell implants. I asked her if anyone had told her chemo, every kind of chemo, can cause balance problems and she said no. No one told me either, and I found out from a trainer at the YMCA. I couldnt understand why when I leaned over to pick something up I would pitch forward. Physical therapy and personal training can assist with this, but we need to know first. This information should be given to every single cancer patient.

I had become increasingly irritated with people at my dentist's office telling me that having one tooth after another crack causing an extraction is due to my hard bite. A hygienist told me airily I had the hardest bite of any patient in the office!

Yes, I am nervous and grind my teeth, I do have bruxism, but to have 5 teeth removed in one year in 2019 is excessive! Finally, my oncologist shared with me that one of the chemos I was on weakens the bone structure. My dentist, who is wonderful, also researched and told me the same thing years after my diagnosis.

My audiologist originally thought my severe drop in hearing loss was due to Presbycusis or aging. I brought in an earlier audiogram to compare the precipitous drop. I then did some research proving the chemo I was on could because hearing loss. She was shocked and immediately went to work to help me.

I started suffering severe stomach pains and my oncologist referred me to a gastroenterologist. He did an endoscopy, found esophageal ulcers, and put me on medication. My PCP tried to tell me it was my age since he knew several patients with this problem. I did not believe him, because I never had problems before. Later the nurse practitioner for the specialist told me that cancer often does cause the ulcers. Again, my research also mentioned any compromised immune system problem such as cancer can lead to this problem that I used to start this conversation.

And, speaking of age, please do not tell me you know how I feel, because you are slowing down from age. Yes I get that and admit as an elderly person it takes me much longer to complete tasks. We all get more tired as we get older. However, that is not the same as the type of fatigue cancer survivors have, where we can be fine and suddenly drop and have to take to bed immediately.

Being forgetful is also part of old age and I know that, but that search for words known to every one of us with chemo brain is scary!

Many cancer survivors experience secondary cancers, total joint replacements from the bone density being reduced and countless other problems from the diseases or treatment. Sometimes it is not cancer-related. Joints do wear out. I have severe arthritis and had a rotator cuff surgery long before my cancer hit. The shoulder is worse now, but it is from gulp age! Our immune systems are affected by cancer too. We may get more frequent infections and need to watch carefully not to be around people who are sick.

Some people may ask if it really matters whether it is related to cancer or not. For us it does. My excellent audiologist keeps in touch with my oncologist and we monitor my remaining hearing. It was my oncologist who referred me to the specialist for the esophageal ulcers. The oncologist is truly unique because they work with so many specialists and family practitioners.

I ask myself why the doctors didnt tell me these side effects. It would take them all day to go over the possible side effects and scare the heck out of us. There are many side effects we will never have. However, it is up to us to know our bodies and to be vigilant in monitoring them. Cancer is an insidious and systematic disease and doesnt affect just one part of our body. However, by having a great relationship with our doctors, doing some basic research to start a dialogue with our doctors, and talking to other survivors, we can help ourselves.

It does not help to become paranoid and think about this all the time. Go read a book, watch a movie, play with your children and grandchildren and enjoy life. You are doing what you should and are better off for it!

See the article here:
Please Quit Telling Me It's Not The Cancer -

Renew Stem Cell and Laser is Expanding Its Offering Outside of Scottsdale – Press Release – Digital Journal

Renew Stem Cell and Laser has a reputation for being a top provider of stem cell and laser treatments in Scottsdale. The high caliber clinic is excited to announce that they are currently expanding their service area to reach all of Arizona. Technicians are available to take appointments and give consultations.

Scottsdale, Arizona - Renew Stem Cell and Laser is excited to announce that starting now, clients all over Arizona will be able to enjoy their state of the art facility. The service menu is going to remain the same, for now. However, more clients will have access to the laser and stem cell therapies that Renew Stem Cell and Laser Scottsdale has to offer.

Renew Stem Cell and Laser is expanded their service areas to include all of Arizona, with the hopes of helping more clients. With multiple services available, clients are expected to flock to the facility. It is unclear yet as to if more services are going to be offered in the future. For now, this one of a kind facility is ready to lend a helping hand to customers outside of Scottsdale. Customers currently in Scottsdale do not have to worry about being pushed to the side. There are enough technicians and open appointments for treatments to accommodate an influx of clients.

This med spa in Scottsdale is excited to reach out to new clients who are in need of services. Consultations are currently being offered to new clients who arent sure which services are right for them. The facility promises that the quality of the treatments will not waiver at all, even though more clients are expected to sign up for services. The prices of services will also remain the same because Renew Stem Cell and Laser is a facility that is dedicated to their clients.

The public is urged to check out what this med spa has to offer in terms of services. Renew Stem Cell and Laser is excited to speak with clients about their facial and body treatments, which involve laser therapy. Many clients are ideal for stem cell therapy and dont even know it. Renew Stem Cell and Laser has decided to raise the bar and extend their service area to branch out to new clients. Numerous people in Arizona can now take advantage of everything on the service menu, without any restrictions.

In the past, Renew Stem Cell and Laser focused their services on the Scottsdale area. Now, the med spa is branching out to expand their service area to include all areas of Arizona. More exciting changes are expected for the future of this one of a kind company. The public is only expected to benefit as this facility makes changes towards bettering their services.

Media ContactCompany Name: Renew Stem Cell and LaserContact Person: Dr. Kerry PhelpsEmail: Send EmailPhone: (480) 869-4666Address:9700 N 91st St Suite B-112 City: ScottsdaleState: AZCountry: United StatesWebsite:

Read the original:
Renew Stem Cell and Laser is Expanding Its Offering Outside of Scottsdale - Press Release - Digital Journal

Stem Cell and Primary Cell Culture Medium Market Analysis And Forecast to 2026 by Recent Trends, Developments in Manufacturing Technology and Regional…

QY Research has lately published a new report titled, *Stem Cell and Primary Cell Culture Medium Market Report 2020 and Forecast to 2026*. The researchers have offered a broad understanding of the industry with the help of research methodologies such as PESTLE Analysis and Porters Five Forces.

Global Stem Cell and Primary Cell Culture Medium Market Outlook to 2026:

The report is just the right resource that global and regional Stem Cell and Primary Cell Culture Medium players and investors need to peep into the future of their business and plan out effective growth strategies. It is a compilation of intelligent and accurate research and analysis studies that help players in the Stem Cell and Primary Cell Culture Medium business to understand the growth patterns of leading segments and regions, nature of competition, and other significant aspects. Buyers of the report are provided with reliable forecasts for total revenue, consumption, sales, CAGR, production, and other important factors.

Click Here For Sample Copy @

The company profiling section of the report provides a brilliant analysis of the growth of leading players in the industry, based on share, recent developments, geographical expansion, regional presence, technology, and many other factors. The vendor landscape is also presented in quite some detail in the report.

This report includes the following manufacturers; we can also add the other companies as you want.MerckSTEMCELL TechnologiesIrvinesciCell Applications, IncBiological IndustriesMiltenyi BiotecSwiss Medica ClinicPromocellCreative BiolabsLifeline Cell TechnologyScienCell Research LaboratoriesOsiris TherapeuticsNuVasiveChiesi PharmaceuticalsJCR PharmaceuticalPharmicellMedi-postAnterogenMolmedTakeda (TiGenix)

Market Segment by TypeLiquid MediaPowder Media

Market Segment by ApplicationBiopharmaceutical ManufacturingTissue Engineering & Regenerative MedicineGene TherapyOther

Some Major Table of Contents

Executive Summary: The report begins with a summary of the entire research study, along with CAGR and value or volume forecasts.

Top Segments: As the name suggests, this section gives details about leading and also other segments, their growth potential, share, and other important factors.

Leading Regions: Here, readers are provided with an in-depth study on key regions and countries and their overall growth during the forecast period.

Company Profiling: This section includes a detailed comparison of top Stem Cell and Primary Cell Culture Medium players, accurate analysis of the competitive landscape, and other studies.

Dynamics: Buyers of the report have access to an intelligent research study on crucial drivers, restraints, trends, and opportunities in the Stem Cell and Primary Cell Culture Medium business.

Conclusion: Here, the analysts authoring the report have provided their overall take on the Stem Cell and Primary Cell Culture Medium business and the industry. This section also includes important findings from the research study.


Read Full Report with TOC @

What the Report has to Offer?

1. Size Forecasts: The report has analysed the industry based on the value and volume over the projected period. Other important parameters including price, capacity, cost, revenue, gross margin, sales revenue, and production are also looked into

2. Future Prospects: The report sheds light on the lucrative business prospects that may prove promising for the players to make future investment

3. Trend Analysis: The readers will gain an insight into the upcoming trends and developments that may take place in the coming future

4. Segmental Analysis: Segments such as application, product type, and end user, along with their contribution to the overall industry size, are analysed by the researchers in this section

5. Regional Analysis: Here, the report examines the present and upcoming developments in varied regions and respective countries

6. Competitive Analysis: The report here discusses about the key strategic initiatives considered by the key players to sustain their hold. This analysis will surely help the competitors in planning their activities ahead

Contact US:QY Research, INC.17890 Castleton, Suite 218,Los Angeles, CA 91748USA: +1 626 428 8800India: +91 9766 478 224Emails [emailprotected]

Original post:
Stem Cell and Primary Cell Culture Medium Market Analysis And Forecast to 2026 by Recent Trends, Developments in Manufacturing Technology and Regional...

Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals – Yahoo Finance

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today highlighted recent progress across several programs and outlined goals for 2020. These updates will be discussed during a webcast presentation at the 38th annual J.P. Morgan Healthcare Conference on Wednesday, January 15th at 11:30 a.m. PT (2:30 p.m. ET).

"In 2019 we generated landmark data from our ADC-based targeted patient preparation platform, which is delivering a new class of antibody-drug conjugates (ADCs) that have the power to bring one-time treatment to more patients with autoimmune diseases, blood cancers and genetic diseases. We also presented clinical data for our first-line stem cell mobilization program, MGTA-145, which we are developing as the new standard of care for stem cell mobilization with the potential to benefit all of the transplant-eligible patients each year," said Jason Gardner, D. Phil., President and Chief Executive Officer, Magenta. "As we begin 2020, we are particularly excited to unveil our MGTA-117 clinical candidate for targeted patient preparation for stem cell transplant or gene therapy. New results announced today highlight the potency, safety and broad therapeutic index of MGTA-117, well above that of currently approved ADCs. We believe that MGTA-117 is the optimal agent for depleting stem cells to enable safe immune reset. We look forward to moving this program into the clinic with initial clinical data expected in 2021."

Targeted Patient Preparation Programs

Current methods to condition patients before transplant and gene therapy are dependent on toxic, non-specific chemotherapy or radiation. These pre-transplant treatments are associated with significant side effects, including infertility, cancer, organ damage and death. Magenta is developing targeted, disease-modifying ADCs that are designed to precisely and rapidly remove the disease-causing cells in the body and enable immune system reset without the need for chemotherapy or radiation.

CD117-ADC Recent Progress

Data presented at the American Society of Hematology (ASH) annual meeting in December 2019, showed the first-ever successful transplant of gene-modified cells in non-human primates using a CD117-targeted, single-agent ADC from Magenta, without the use of chemotherapy or radiation. These unprecedented results validate and advance Magentas conditioning platform.

Building on this work, Magentas new clinical candidate, MGTA-117, is a CD117 antibody conjugated to amanitin. Results published today in an abstract for the Transplant and Cellular Therapy annual meeting show that MGTA-117 potently depleted stem and progenitor cells and demonstrated a wide tolerability: potency ratio of 30 fold (therapeutic index; typical range for approved ADCs at this stage is two to six fold). This program is advancing to the clinic and further validates Magentas antibody drug conjugate-based conditioning platform. MGTA-117 was developed under a partnership with Heidelberg Pharma that grants Magenta exclusive worldwide development and marketing rights for ADCs using an amanitin payload and targeting CD117.

MGTA-117 in 2020

Magenta is scaling up manufacturing of MGTA-117 and completing IND-enabling studies in 2020. The Company intends to move this new product candidate into the clinic with initial clinical data expected in 2021.

CD45-ADC Recent Progress

Current standard treatment for patients with multiple sclerosis involves years of chronic dosing of medications that do not halt the progression of the disease. For patients with systemic sclerosis, a potentially fatal autoimmune disease, there are no approved therapies. Immune reset through stem cell transplant has demonstrated durable remissions in thousands of patients with autoimmune diseases such as multiple sclerosis and systemic sclerosis, and it is recommended by the European League Against Rheumatism (EULAR) in treatment guidelines for systemic sclerosis. The immune reset process involves two main steps: removing the disease-causing cells and replacing them with healthy cells to rebuild the immune system to a healthy state.

Magenta is developing targeted ADCs designed to precisely remove the disease-causing cells in the body without the need for chemotherapy or radiation. Magentas CD45-ADC program targets CD45, a protein expressed on immune cells and stem cells and is designed to remove the cells that cause autoimmune diseases in order to enable curative immune reset.

Story continues

Data presented at the American College of Rheumatology (ACR) meeting in November 2019 showed that a single dose of CD45-ADC removed disease-causing reactive T cells, enabled successful immune reset and rebuild of the immune system and was well tolerated in three models of autoimmune disease, including the EAE model, the most reliable murine model of multiple sclerosis. Further, a single dose of CD45-ADC significantly reduced disease incidence and delayed disease onset in this model that has successfully provided preclinical proof of concept for many clinically validated standard-of-care therapies.

CD45-ADC in 2020

Magenta has identified a lead antibody and has progressed this program into IND-enabling studies, which the Company plans to further advance in 2020.

MGTA-145 First-Line Stem Cell Mobilization Therapy

MGTA-145 Recent Progress

Magenta is developing MGTA-145 as the new first-line standard of care for stem cell mobilization in a broad range of diseases, including autoimmune diseases, blood cancers and genetic diseases. MGTA-145, a CXCR2 agonist, works in combination with plerixafor, a CXCR4 antagonist, to harness the physiological mechanism of stem cell mobilization.

Magenta is currently studying MGTA-145 and plerixafor in a Phase 1 study in healthy volunteers. Data from the Phase 1 study presented at the ASH annual meeting in December 2019 showed that MGTA-145 in combination with plerixafor successfully enables safe, same-day dosing, mobilization and collection of sufficient high-quality hematopoietic stem cells for transplant. Further, when cells collected from the first two apheresis subjects were transplanted into humanized mice, the cells engrafted more rapidly and at a five-fold higher level than cells from G-CSF-mobilized peripheral blood.

MGTA-145 in 2020

Magenta intends to complete the Phase 1 study and move this program into multiple Phase 2 studies in patients in 2020. The Phase 2 studies will include both allogeneic and autologous transplant settings and will evaluate mobilization and collection of high-quality cells and engraftment of the cells after transplant.

MGTA-456 Cell Therapy

MGTA-456 Recent Progress

MGTA-456 is a cell therapy designed to provide a high dose of stem cells that are well matched to the patient to enable safe immune and blood system rebuild and durable remissions in patients with blood cancers. In September, the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation for MGTA-456 for the treatment of multiple inherited metabolic disorders.

Magenta is currently studying MGTA-456 in a Phase 2 study in patients with inherited metabolic disorders, including cerebral adrenoleukodystrophy (cALD) and Hurler syndrome. These are rare, rapidly progressive neurologic disorders that are fatal when left untreated. Results in the first two evaluable patients with cALD updated in December 2019 showed early and durable resolution of the disease at 12 months follow-up. The Loes score and NFS score, which measure progress of the disease, remained stable, suggesting that progress of the disease has been halted in these patients. The early and durable resolution of disease with MGTA-456 is not consistently seen with other therapies, including standard stem cell transplant, gene therapy or enzyme replacement therapy.

MGTA-456 in 2020

Magenta intends to complete enrollment in the Phase 2 in 2020 and continue dialogue with the FDA under the RMAT designation, and to discuss with the European Medicines Agency (EMA) for development in Europe

About Magenta Therapeutics

Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of unmet need, Magenta Therapeutics is pioneering an integrated approach to allow more patients to receive one-time, curative therapies by making the process more effective, safer and easier.

Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "will," "could", "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "seeks," "endeavor," "potential," "continue" or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption "Risk Factors" in Magentas Annual Report on Form 10-K, as updated by Magentas most recent Quarterly Reports on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

View source version on


Magenta Therapeutics:Manisha Pai, Vice President, Communications & Investor

Read more here:
Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals - Yahoo Finance

AgeX Therapeutics to Participate at Four Conferences in January 2020 – Yahoo Finance

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that the company will present at the following four conferences this month: Biotech Showcase, January 13-15; Precision Medicine World Conference (PMWC 2020), January 21-24; World Stem Cell Summit, January 21-24; and Longevity Therapeutics, January 28-30.

Details of the companys presentations follow:

Biotech Showcase January 13-15 at the Hilton San Francisco Union Square, San Francisco, CaliforniaAgeX session: Wednesday, January 15, 9:00am PST.

AgeXs founder and CEO Michael D. West, PhD will deliver a presentation on AgeX and its programs at this investor conference held concurrently with the J.P. Morgan Healthcare Conference.

World Stem Cell Summit January 21-24 at the Hyatt Regency Miami, Miami, Florida.

AgeX will participate in a 90-minute session that will include two talks as well as a panel discussion, on Thursday, January 23, 1:45-3:15pm EST. Dr. West will deliver a 25-minute presentation, "Towards safe in vivo partial reprogramming with induced tissue regeneration" while AgeXs VP, Discovery Research, Dana Larocca, PhD, will deliver a presentation, "Derivation and uses of highly pure, non-immunogenic lineage-specific stem cell lines."

Additionally, three AgeX team members will participate on a panel discussion, "The next stem cell revolution: transcending limits on purity, immunogenicity and oncogenicity." Panel participants include Drs. West and Larocca, in a session moderated by Dr. Aubrey de Grey, AgeXs VP, New Technology Discovery.

Precision Medicine World Conference (PMWC 2020) January 21-24 at the Santa Clara Convention Center, Santa Clara, CaliforniaAgeX Session: Thursday, January 23, 3:30pm PST.

AgeXs CFO Russell Skibsted will deliver a corporate presentation as part of the Emerging Therapeutics Track.

Longevity Therapeutics January 28-30 at the Holiday Inn Golden Gateway Hotel, San FranciscoAgeX session: Wednesday, January 29, 1:30pm PST.

Dr. Larocca will deliver a presentation on AgeXs induced tissue regeneration (iTR) program.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

For more information, please visit or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates" should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the "Risk Factors" section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

View source version on


Media Contact for AgeX:

Bill Douglass Gotham Communications, (646) 504-0890

See original here:
AgeX Therapeutics to Participate at Four Conferences in January 2020 - Yahoo Finance

Imber Medical has what we’ve all been waiting for – Brunswick News

The word enthusiasm comes to mind when you meet Dr. Slack, MD and her team. Even the building itself has an air of newness and excitement. Dr. Slack begins to tell me about what is available at Imber and Im surprised that I have never heard of several of these treatments.

I see her face light up as she explains how much these treatments have helped people. And that for some, aesthetics treatments can be better than Prozac! The latest treatment acquired is the EMSCULPT. This is a machine that uses magnetic energy to initiate contractions of the muscles 20,000 contractions in 30 minutes to be exact!

This leads to formation of new muscle fibers and improvement in core strength that continues for years! Studies show that EMSCULPT not only increases muscles but induces 20% fat reduction (as a glorious side effect). These results have been confirmed by MRIs so there is no guesswork as to the devices effectiveness. What is amazing about this machine is that you get the benefits of doing 20,000 sit-ups while lying down and relaxing. No sweating, no pain, no shortness of breath or increase in heart rate.

This is a fantastic option for anyone who has trouble building up their muscles because of time constraints, back pain, child- birth or even hitting that dreaded plateau at the gym. Ladies love the flat stomachs, toned abs and improvements in physical ability appreciated during yoga, pilates, and tennis! Men have become huge fans after seeing how the results of strengthening ones core affects their golf game!

We first realized there was a demand for EMSCULPT in the Golden Isles when several existing clients expressed how much it had helped their back pain when treated with EMSCULPT at an Atlanta clinic says Dr. Slack. What sold our team was the before and after pictures which speak for themselves. But I was even more impressed with the data and shocked to learn that this device is the only non-surgical, FDA approved option for treatment for diastasis recti (the separation of stomach muscles that occurs during pregnancy). Life brings a lot of changes and how we look, and feel can greatly impact our confidence. What Imber offers is the latest solutions that are proven to work.

EMSCULPT is also FDA approved for building the muscles of the abs, glutes, arms and legs. I cant help but think that this is the perfect time of year. Valentines Day, and shorts season will be here before we know it!

Dr. Slack goes on to list other novel treatments. She shares with me information on Verju, a FDA approved, pain-free, non-surgical, fat reducing (non-hot, non- cold) laser. That consistently delivers results of 4 inch overall circumference reduction after just 6 treatments.

If that wasnt enough to blow my mind she went on to tell me about PDO Threads. She describes how these FDA approved threads can lift the face and smooth out wrinkles while building collagen. Plasma Pen was mentioned next. which is an FDA approved treatment for a non-surgical eyelid lift and wrinkle removal. PRP (Platelet Rich Plasma) is another option in the fight to revitalize the skin. Like the Plasma Pen, PRP is 100% natural and organic which is important to the Imber team!

Even the staples of aesthetics like Botox and filler treatments are taken to a whole new level. Dr. Slack is so proud of her team consisting of herself as an aesthetics board certified MD and advanced registered nurse practitioners. Imbers master injector, Bianca Trevino ARNP, is also board certified in aesthetics and able to provide Botox injections in areas I had never heard of! She can upturn the corners of a down turned mouth, lower the lip of a gummy smile, prevent the tip of a nose from pulling down, provide brow lifts, jaw definition, fine line and wrinkle reduction with micro-Botox and even eliminate neck bands! With regard to filler, the advanced training really shows with their results in providing a natural and youthful appearance, never looking overdone. Imber has virtually every toxin and filler available and the knowledge of what needs to be used when. Bioidentical hormone therapy, IV hydration therapy, hair restoration for men and women, intimacy treatments, jaw contouring, medical assisted weight loss, scar revision, acne treatment and so much more is offered at Imber.

When combining the above treatments with medical grade products (including stem cell and sun protection) sold at Imber: prevention, correction and maintenance are all optimized.

In finishing up my visit, Dr. Slack tells me Our clinics goal is to provide the latest FDA approved solutions available to help all of the Golden Isles look and feel like the best version of themselves. We are so blessed to be a part of this wonderful community and look forward to giving it the best the World has to offer.

If you would like to learn more, Imber hosts a Thirsty Thursday event every 3rd Thursday of the month for those who Thirst for Knowledge ...or wine! Join Imber Jan 16th to learn more about Emsculpt or any other services Imber offers!

Excerpt from:
Imber Medical has what we've all been waiting for - Brunswick News

Tacitus Therapeutics Launches in Collaboration with Mount Sinai to Develop Stem Cell Therapies for Life-Threatening Diseases – Yahoo Finance

Tacitus Therapeutics exclusively licenses technology for expansion, differentiation and engineering of hematopoietic stem cells for use in therapeutic applications

NEW YORK, Jan. 9, 2020 /PRNewswire/ -- Tacitus Therapeutics, a clinical-stage company, has launched in collaboration with the Mount Sinai Health System to develop stem cell therapies initially targeting blood cancers and related clotting disorders. Their first therapy, HSC100, currently is being investigated in a Phase I clinical trial1.

Tacitus is building upon technology developed by and exclusively licensed from Mount Sinai. Based on research by scientific co-founders Ronald Hoffman, M.D., and Camelia Iancu-Rubin, Ph.D., the technology includes proprietary cell expansion, differentiation and engineering methods. Together, these methods manufacture healthy cells that overcome the limitations of traditional allogeneic, or donor, cell transplantations.

Blood cancers comprise about 10% of new cancer cases in the U.S. each year, and almost 60,000 people die from blood cancer complications annually. Most blood cancers start in the bone marrow, where blood is produced. A common therapy for such blood cancers is a hematopoietic stem cell (HSC) treatment or, as more commonly referred to, bone marrow transplantation. In this process, doctors infuse healthy HSCs into the patient's bloodstream, where they migrate to the bone marrow to grow or engraft.

HSCs for this process can be collected from bone marrow, circulating blood, or umbilical cord blood (CB) of healthy donors. While HSC transplants are common, significant barriers to success exist, including high levels of graft-versus-host disease, low numbers of healthy cells obtained from CB, and increased risk of bleeding due to delayed megakaryocyte, or platelet, engraftment.

Hoffman and Iancu-Rubin are pioneers of bone marrow cell therapy treatments, and development of this technology was enabled by the New York State Stem Cell Science program, NYSTEM. As a New York State Department of Health initiative, NYSTEM awarded a $1 million grant to Hoffman in 2010 that supported the original research underpinning this platform technology. In 2015, NYSTEM awarded Hoffman and Iancu-Rubin an $8 million grant to translate the technology from the laboratory into the clinic, where it is currently in clinical trial1.

Hoffman also serves as Director of the Myeloproliferative Disorders Research Program and Professor of Medicine (Hematology and Medical Oncology) and Iancu-Rubin is Associate Professor of Pathology at the Icahn School of Medicine and Director of the Cellular Therapy Laboratory at Mount Sinai Hospital.

"Promising discoveries by Mount Sinai scientific thought leaders may lead to new, essential cell-based therapies that will broadly benefit patients," said Erik Lium, Executive Vice President and Chief Commercial Innovation Officer, Mount Sinai Innovation Partners. "We're pleased to be collaborating with Tacitus to launch the next stage of development for these technologies."

"Tacitus is committed in its mission to advance next-generation cell therapies with curative potential," said Carter Cliff, CEO of Tacitus. "Based on our founders' solid foundation of research, we are translating these discoveries into broad clinical practice as we look to dramatically improve the standard of care for patients with life-threatening conditions."

About HSC100

HSC100 is an investigational therapy based on allogeneic hematopoietic stem cells (HSC) expanded from umbilical cord blood. HSC100 is being investigated currently in an open-label Phase I clinical trial1 in the United States for treatment of hematological malignancies. The success of unmanipulated cord blood as a source of stem cells has been hampered by the small number of stem cells present in a single cord, leading to delayed engraftment and frequent graft failure. Our proprietary technology includes the use of an epigenetic modifier, valproic acid, to expand the number and the quality of HSCs found in cord blood collections. For more information on HSC100 clinical trials, please visit identifier NCT03885947.

About Tacitus Therapeutics

Tacitus Therapeutics is a clinical-stage biotechnology company developing advanced medicines for treatment of blood cancers, immune disorders and other intractable disease conditions. Our mission is to pioneer best-in-class therapies using proprietary cell expansion, differentiation and engineering platform technologies that overcome the limitations of traditional cell transplantation. Initial targets include a lead clinical program (HSC100) investigating the treatment of blood cancers, followed by preclinical programs to address clotting disorders and other serious unmet medical needs. For additional information, please visit

Story continues

About Mount Sinai Health System

The Mount Sinai Health System is New York City's largest integrated delivery system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The Health System includes approximately 7,480 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 12 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Geriatrics, Gynecology, Nephrology, Neurology/Neurosurgery, and Orthopedics in the 2019-2020 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 12th nationally for Ophthalmology, Mount Sinai St. Luke's and Mount Sinai West are ranked 23rd nationally for Nephrology and 25th for Diabetes/Endocrinology, and Mount Sinai South Nassau is ranked 35th nationally for Urology. Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and Mount Sinai South Nassau are ranked regionally. For more information, visit or find Mount Sinai on Facebook, Twitter and YouTube.

About Mount Sinai Innovation Partners (MSIP)

MSIP is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and inventions and the development of research partnerships with industry. Our aim is to translate discoveries and inventions into health care products and services that benefit patients and society. MSIP is accountable for the full spectrum of commercialization activities required to bring Mount Sinai inventions to life. These activities include evaluating, patenting, marketing and licensing new technologies building research, collaborations and partnerships with commercial and nonprofit entities, material transfer and confidentiality, coaching innovators to advance commercially relevant translational discoveries, and actively fostering an ecosystem of entrepreneurship within the Mount Sinai research and health system communities. For more information, please visit http://www.ip.mountsinai.orgor find MSIP onLinkedIn, Twitter, Facebook,Medium, and YouTube.

Media Contacts:

Mount Sinai Cynthia Cleto Mount Sinai Innovation Partners (646) 605-7359

Tacitus TherapeuticsJoleen RauRau Communications(608)

View original content:

SOURCE Tacitus Therapeutics

See more here:
Tacitus Therapeutics Launches in Collaboration with Mount Sinai to Develop Stem Cell Therapies for Life-Threatening Diseases - Yahoo Finance

Global Amniotic Membrane Market 2020-2024 | Evolving Opportunities with Celularity Inc. and Human Regenerative Technologies LLC | Technavio – Business…

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global amniotic membrane market since 2019 and the market is poised to grow by USD 1.48 billion during 2020-2024, progressing at a CAGR of more than 13% during the forecast period. Request a free sample report

Read the 145-page report with TOC on Amniotic Membrane Market Analysis Report by Geography (Asia, Europe, North America, and ROW), Type (Cryopreserved amniotic membrane and Dehydrated amniotic membrane), and the Segment Forecasts, 2020-2024.

The market is driven by the rising demand for biocompatible scaffolds. In addition, the rise in the development of new applications through research is anticipated to boost the growth of the amniotic membrane market.

The rising need for naturally derived materials in tissue scaffolding is increasing the demand for amniotic membranes. This is due to the specialized structure of amniotic membranes that exhibit high biological viability, making them ideal for creating bio-scaffolds. Moreover, the epithelial cells in amniotic membranes have the advantages of stem cells which provide a native environment of cell seeding. Bio-scaffolds are widely used in regenerative therapies for the treatment of bone, cartilage, skin, vascular tissues, and skeletal muscles. With growing geriatric population, the demand for such orthopaedic regenerative therapies is expected to increase significantly during the forecast period. This will have a positive impact on the demand for amniotic membranes.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Amniotic Membrane Market Companies:

Celularity Inc.

Celularity Inc. operates its business through the Unified Business Segment. BIOVANCE is the key offering of the company. It offers a decellularized, dehydrated human amniotic membrane allograft that contains natural extracellular matrix (ECM) that helps in wound regeneration and tissue restoration.

Human Regenerative Technologies LLC

Human Regenerative Technologies LLC operates the business across segments such as Flowable and Membrane. HydraTek amniotic membrane products, is the key offering of the company. It includes thin and thick dehydrated amniotic membranes used in covering and protecting the recipient's tissue.

Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corp. operates its business across segments such as Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers a wide range of amniotic membrane products. Some of the key offerings include AmnioExcel Amniotic Allograft Membrane, BioDDryFlex Amniotic Tissue Membrane, BioDOptix Amniotic Extracellular Membrane, and Integra BioFix Amniotic Membrane Allograft.

Katena Products Inc.

Katena Products Inc. operates the business across segments such as Instruments, Biologics, Plugs, Lenses, Devices, and Blink Medical. Amniotic Membrane Surgical and Amniotic Membrane Clinic are some of the key offerings of the company.

MiMedx Group Inc.

MiMedx Group Inc. operates the business in the Regenerative biomaterial products and bioimplants segment. The company offers a wide range of amniotic membrane products. AmnioFix, EpiFix, and EpiBurn are the key offerings of the company.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Amniotic Membrane Type Outlook (Revenue, USD Billion, 2020 - 2024)

Amniotic Membrane Regional Outlook (Revenue, USD Billion, 2020 - 2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Healthcare include:

Global Extracorporeal Membrane Oxygenation Machines Market Global extracorporeal membrane oxygenation machines market by geography (Asia, Europe, North America, and ROW) and modality (veno-venous and arterio-venous; and veno-arterial).

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Global Duchenne muscular dystrophy (DMD) therapeutics market by type (biologics and small molecules) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at

Read more:
Global Amniotic Membrane Market 2020-2024 | Evolving Opportunities with Celularity Inc. and Human Regenerative Technologies LLC | Technavio - Business...

The most important health innovations of the past decade – The Hill

The 2010s are coming to an end, and looking back there have been some pretty amazing advances and innovations in health and science.

Advances in prosthetic limbs

Prosthetic limbs have been around since ancient times. In Egypt, a prosthetic wooden toe was found on a mummy dating back 3,000 years. By the Dark Ages, inventors could incorporate hinges on prosthetic arms used by knights. In modern times, the field of prosthetics has turned to incorporating more technology into physical stand-ins for limbs. In the last several years, theres been a boom in advances that have led to the best and most useful prosthetics weve ever seen.

Reports from the early 2010s talked about the potential for new technology to allow people to control prosthetics with their minds and to receive sensory information from their devices. It may have been a reach in the early part of the decade, but now it is literally within grasp. There are new prosthetic hands being tested that give the user the ability to grab objects with their thoughts and even to sense the texture of what they are touching. New bionic hands allow the user to feel again by sending signals back to the brain about the things they are touching, like whether its hard or soft. Other research groups have been working on bionic arms that can move based on the users thoughts through a brain-computer interface. While these have demonstrated its possible to accomplish these goals in the lab, theres still more to be done before people can use these devices outside in the real world.

Many of these advanced prosthetics are still prototypes and may not reach the general population for a while. Luckily, cheaper 3D printers have made simple prosthetics more accessible. These are important because a prosthetic device can improve the quality of life for people. For example, this person has been printing prosthetic hands and arms for people in Africa after watching an online tutorial. New materials that go into 3D printers are cheaper than they used to be and are being used in prosthetics to provide a more affordable option for patients.

Although prosthetics have been around for ages in some form or another, they arent always used. One variable to consider is the social acceptance of having a prosthetic. Theres still a lot of stigma around disabilities and many people may reject prosthetics even if they are available. In 2012, an athlete with both feet amputated competed in the mens 400 meter race at the Olympics in London. There was some controversy over whether the runner with a prosthetic foot should be allowed to run in races with people who dont have prosthetics or if they should only be allowed in competitions specifically for people who have them. Prosthetics also need to be comfortable and usable in order to be successfully adopted. In one study, about 4.5 percent of people rejected prosthetics and 13.4 percent stopped using their prosthetics. As the new prosthetics that are more natural and intuitive to use come to market, hopefully more people will benefit, and the social barriers to acceptance will disappear.


The genome modification technique called Clustered Regularly Interspaced Short Palindromic Repeats, aka CRISPR, was a culmination of a few decades of work by scientists, and major studies explaining the method were published in 2013. The version of it called CRISPR-associated protein 9 or CRIPSR-Cas9 is what most researchers are specifically using in most cases. It involves a regular gene editing mechanism that happens in bacteria. The bacteria can take sections of DNA from attacking viruses and essentially use that to remember the viruses if they return. When the virus is back, the bacteria can target the matching sections of DNA in the virus, cut it and disable the virus.

Though 2013 was only six years ago, as far as science goes, CRISPR has been moving at lightning speed towards practical applications. Using CRISPR to edit a gene sequence, researchers can now add, delete or modify DNA segments more quickly and accurately than ever before. Since the technique was developed, researchers have used CRISPR to target diseases caused by a single gene like cystic fibrosis or sickle cell disease.

Probably the most infamous use of CRISPR are the CRISPR babies. In late 2018, a Chinese researcher, He Jiankui, claimed to have used CRISPR to modify the genomes of two babies to include a mutated version of a gene that protects against HIV. This case was and is highly controversial for the ethical concerns with genetically modifying a human genome at the embryo level, or germline, meaning it can be passed down to future generations and has not been done before in humans. Recently, MIT Technology Review obtained excerpts from Hes research, and experts say that the report and data may be untrustworthy. This means it is still unclear if He and collaborators actually successfully modified the babies genomes. The scientific community overall condemns this way of using CRISPR to edit a human germline genome and has called for an international moratorium on it until a framework can be agreed on.The researcher has been sentenced to three years in prison in Shenzhen, China.

As fraught with controversy as the CRISPR babies may be, CRISPR technology still holds a lot of promise and can be used responsibly, supporters say. For example, researchers are using it to target cancer cells by taking a patients immune cells, modifying them using CRISPR and then infusing the patient with the modified cells. For blood diseases, a patient with sickle cell disease is reported to be responding well to a CRISPR treatment that has allowed her body to produce a crucial protein.

Another area that has boomed this decade partly because of CRISPR technology is stem cell therapy, which well get into in the next section.

Stem cell therapy

Technically, the only Federal Drug Administration (FDA)-approved stem cell therapies are blood-forming stem cells derived from umbilical cord blood. Blood-forming stem cells are used to treat patients with cancer after chemotherapy has depleted blood cells, as well as patients with blood disorders like leukemia whose bone marrow tissues are damaged. These types of treatments have been around for about 30 years, but in the 2010s weve seen potential for more uses of stem cells in health care.

The main idea behind stem cell therapy is that because the cells are pluripotent meaning they can become many other types of cells they can be introduced into parts of the body that are damaged and need new cells. On top of that, researchers can now extract some types of stem cells from a persons body, so no need for umbilical cords. This opens up the possibilities for highly personalized treatment where one person can be treated with stem cells from their own body.

Researchers are exploring how stem cells can be used to treat liver disease, cerebral palsy, stroke, brain injury and others. There are many ongoing research-backed clinical trials for stem cell therapy. A quick search for stem cell therapy on the governments clinical trial database turns up 5,638 results. And because of the work necessary to even get to the clinical trial stage, theres likely an order of magnitude more stem cell therapy studies in the pre-clinical trial stages.

Stem cell therapy is also being offered in for-profit clinics around the U.S. In these cases, the clinics are typically taking fat tissue from a patient, isolating the stem cells and then administering the stem cells back to the patient. In some cases, the treatments may lead to health complications, like blindness in a few extreme cases, and the FDA warns that such treatments are unapproved and potentially harmful. The FDA is ramping up regulation of stem cell clinics and earlier this year took a specific clinic in Florida to court.

Although there are many stem cell clinics offering unproven stem cell therapies, its not all hype. Granted that its difficult to pass the clinical trial stage to get FDA approval, stem cell research may lead to new treatments for several health conditions that could completely change the health care landscape.

You can follow Chia-Yi Hou on Twitter.

Here is the original post:
The most important health innovations of the past decade - The Hill